December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025
Go back

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

  • The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
  • We seek application-oriented ideas with strong implementation potential and high market opportunities.
  • Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

  • Scientists from universities and non-university institutions
  • Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
  • Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

  • Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
  • Presentation to an international audience, financiers, and the trade press
  • Three awards, each worth €2,000
  • An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.

TO THE APPLICATION
Innopreis_2025_Flyer_EDownload

Our latest News

discover more
Interdisciplinary Care for Elderly Trauma Patients: Heidelberg University Hospital’s Center for Geriatric Trauma Receives Certification

Interdisciplinary Care for Elderly Trauma Patients: Heidelberg University Hospital’s Center for Geriatric Trauma Receives Certification

The German Society for Trauma Surgery has jointly certified the Department of Trauma and Reconstructive Surgery at Heidelberg University Hospital (UKHD) and Agaplesion Bethanien Hospital Heidelberg as a Geriatric Trauma Center. The certification recognizes the outstanding care provided to elderly trauma patients at UKHD and underscores the great importance of interdisciplinary geriatric medicine. Full text […]

read more
Tony Hyman starts as EMBL Director General

Tony Hyman starts as EMBL Director General

Former EMBL group leader returns to lead the organisation’s six sites at a time of change and opportunity in life sciences EMBL welcomes its new Director General, Tony Hyman, who will take up the mandate of leading EMBL’s six sites as the organisation enters its next phase. Hyman succeeds Interim Director Ewan Birney, who assumed leadership […]

read more
New Mouse Model: Rhabdomyosarcoma GEMM

New Mouse Model: Rhabdomyosarcoma GEMM

We are very proud to be a part of a joint, international effort to develop a genetically engineered mouse model (GEMM) for the understudied pediatric cancer, alveolar rhabdomyosarcoma (aRMS). This model, which has been deposited at JAX (strain 041178), will accelerate the development of living-saving therapies for children with aRMS. This model was developed as a […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp